September pricing snapshot: LillyDirect self-pay is now identical for Zepbound pens and vials

A September 2, 2026 pricing snapshot found that Eli Lilly's LillyDirect self-pay program now charges identical prices for Zepbound KwikPens and single-dose vials ^[1]. At the 2.5 mg starting dose, both forms cost $299 a month. At 5 mg, both cost $399. From 7.5 mg and up, both cost $449, as long as the patient refills within 45 days ^[1]. Those self-pay prices sit well below the regular prices, which range from $599 to $1,049 ^[1].

Lilly's other GLP-1, the pill orforglipron sold as Foundayo, runs cheaper at the bottom of its dose range. Self-pay is $149 at the 0.8 mg starting dose. The 2.5 mg dose is also $149, but only temporarily, through December 31, 2026 ^[1]. The 5.5 mg dose costs $199. The three highest doses cost $299 each ^[1]. Reuters reported the same broad structure as part of Lilly's pricing agreement with the Trump administration, describing Zepbound as available from $299 up to $449 a month and Foundayo starting at $149 through LillyDirect ^[2].

TrumpRx.gov, the federal portal that links patients to manufacturers' own self-pay programs, listed four GLP-1 drugs on September 2 ^[1]. Foundayo and Lilly's diabetes drug Mounjaro were not among them ^[1]. The site's Zepbound page does not sell the drug directly; it routes buyers to LillyDirect ^[1].

These self-pay prices exist alongside other coverage paths. The Medicare GLP-1 Bridge, running from July 1, 2026 through December 31, 2027, sets a flat $50 copay per 30-day fill for eligible Part D members using Wegovy, Zepbound KwikPen, or Foundayo, with Medicare covering a net $245 a month for each fill under a most-favored-nation pricing deal ^[1]. Manufacturer list prices remain far higher than what most patients pay: Wegovy's list price is $1,349.02 and Ozempic's is $1,027.51, though the snapshot noted that almost nobody pays those sticker prices ^[1]. Separately, Zepbound is set to return to CVS Caremark's commercial formulary on October 1, 2026 ^[1].

Why it matters for patients

For people weighing Zepbound, the pricing snapshot means the choice between a multi-dose pen and a single-dose vial no longer comes with a price difference through LillyDirect's self-pay channel — both cost the same at each dose level ^[1]. That could simplify decisions for patients who previously might have picked one form over the other partly based on cost.

The gap between Zepbound and Foundayo self-pay prices remains notable at the entry level, with Foundayo priced at $149 versus $299 for Zepbound's lowest dose ^[1]. But that comparison only applies to people paying out of pocket through LillyDirect; insurance coverage, formulary status, and the Medicare Bridge copay can change what any individual patient actually pays.

The absence of Foundayo and Mounjaro from TrumpRx.gov's list on this date is a reminder that patients cannot assume every GLP-1 drug is available through every government-linked pricing tool. Anyone comparing prices needs to check the specific channel — LillyDirect, NovoCare, TrumpRx.gov, or the Medicare Bridge — since terms and covered drugs differ across them ^[1].

What happens next

The temporary $149 self-pay price for Foundayo's 2.5 mg dose is set to run only through December 31, 2026, after which the price is expected to change ^[1]. CVS Caremark's commercial formulary is scheduled to add Zepbound back on October 1, 2026 ^[1]. The Medicare GLP-1 Bridge program itself runs through December 31, 2027 ^[1]. Separately, the FDA's proposal to remove semaglutide and tirzepatide from the list of drugs eligible for bulk compounding had its comment period close July 30, 2026, with no final rule issued as of the September 2 snapshot ^[1].